Latest News

MaxCyte to Present at Piper Jaffray 30th Annual Healthcare Conference

 

Gaithersburg, Maryland – November 21, 2018: MaxCyte announced today that Doug Doerfler, Chief Executive Officer, will present a company overview at the Piper Jaffray 30th Annual Healthcare Conference on Wednesday, November 28, 2018, at 1:10 p.m. ET in New York City.

 

About MaxCyte
MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte’s mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology platform to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 55 partnered program licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com

 

For further information, please contact:

MaxCyte Inc
Doug Doerfler, Chief Executive Officer+1 301 944 1660
Ron Holtz, Chief Financial Officer
Claudia Dansky Ulmann, MD, Chief Medical Officer

 

Financial PR Adviser
Consilium Strategic Communications+44 (0)203 709 5700
Mary-Jane Elliottmaxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji

 

US Media Relations
Jamie Lacey-Moreira+1 410 299 3310
jamielacey@presscommpr.com

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Request Demo